論文

査読有り 筆頭著者
2021年3月18日

Role of surgery in a novel multimodal therapeutic approach to complete cure of advanced lung cancer: current and future perspectives.

Surgery today
  • Masaomi Yamane
  • ,
  • Shinichi Toyooka

記述言語
英語
掲載種別
研究論文(学術雑誌)
DOI
10.1007/s00595-021-02228-2

Non-small cell lung cancer (NSCLC) is considered potentially curable by multimodal therapy in a subset of patients, including those with locally advanced (LA) disease or nodal spread, who would otherwise have a poor prognosis. Guidelines recommend perioperative chemotherapy with platinum-based regimens, with or without radiotherapy, as the standard treatment modality for high-risk resectable LA-NSCLC. Although the classical regimens of adjuvant chemotherapy have been platinum-based doublet or oral agents such as tegafur/uracil, some molecular targeted therapeutic agents and immune checkpoint inhibitors have been developed recently with an expected favorable effect. Recent trials of perioperative therapy using these agents have demonstrated favourable anticancer efficacy for LA-NSCLC with an acceptable adverse events profile. The ideal timing of perioperative therapy administration, before or after surgery, is still controversial. Because some speculation and concepts have arisen from basic research, several trials are ongoing to clarify the efficacy of newly developed agents in the adjuvant or neoadjuvant setting. This review discusses the role of surgery in the new era and analyzes when and which optimal perioperative multimodal therapy, including chemotherapy, radiotherapy, molecular-targeted therapy, and immunotherapy, should be administered for resectable or potentially resectable NSCLC to provide possible complete cure.

リンク情報
DOI
https://doi.org/10.1007/s00595-021-02228-2
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/33738585
ID情報
  • DOI : 10.1007/s00595-021-02228-2
  • PubMed ID : 33738585

エクスポート
BibTeX RIS